Results 51 to 60 of about 2,545,005 (248)

Cost-effectiveness of rhythm control strategy: Ablation versus antiarrhythmic drugs for treating atrial fibrillation in Korea based on real-world data

open access: yesFrontiers in Cardiovascular Medicine, 2023
BackgroundAblation-based treatment has emerged as an alternative rhythm control strategy for symptomatic atrial fibrillation (AF). Recent studies have demonstrated the cost-effectiveness of ablation compared with medical therapy in various circumstances.
Woojin Kim   +7 more
doaj   +1 more source

How to Choose Between Rate and Rhythm Control Strategy

open access: yesMajalah Kardiologi Indonesia, 2013
Atrial fibrillation (AF) is common and highly variable in its clinical presenta-tion and evolution. Iit causes substantial morbidity and mortality, including impaired quality of life, heart failure, systemic emboli, and stroke.
Dicky A Hanafy
doaj   +1 more source

Antiarrhythmic Drug Therapy in Arrhythmogenic Right Ventricular Cardiomyopathy

open access: yesBiomedicines, 2023
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a heritable progressive myocardial disorder that predisposes patients to ventricular arrhythmias and sudden cardiac death.
Sean P. Gaine, Hugh Calkins
doaj   +1 more source

From nature to nanoscale: advances, challenges, and preclinical translation of nanofiber drug delivery systems containing plant‐derived active ingredients

open access: yesJournal of the Science of Food and Agriculture, EarlyView.
Abstract Since the early 1960s, nanotechnology has been a critical area of science, allowing for the development of sophisticated nanomaterials. Nanofibers, one of the most widely used nanotechnological drug delivery systems, have emerged as a highly versatile platform within modern pharmaceutical sciences.
Heybet Kerem Polat   +7 more
wiley   +1 more source

Recent Advances in Antiarrhythmic Drug Therapy

open access: yes, 2023
Cardiac arrhythmias remain a common cause of death and disability. Antiarrhythmic drugs (AADs) and antiarrhythmic agents remain a cornerstone of current cardiac arrhythmia management, despite moderate efficacy and the potential for significant adverse ...
Dobromir Dobrev   +6 more
core   +1 more source

Transplacental Flecainide and/or Digoxin for Fetal Tachyarrhythmias: Therapeutic Efficacy and Clinical Experience

open access: yesPrenatal Diagnosis, EarlyView.
ABSTRACT Objective To assess the efficacy and safety of transplacental flecainide and/or digoxin for fetal tachyarrhythmias when sotalol is unavailable. Method We evaluated transplacental flecainide, digoxin, or combination therapy in a retrospective and prospective cohort across two Thai tertiary centers.
Mukpradab Darakamas   +6 more
wiley   +1 more source

ANTIARRHYTHMIC ACTION OF CARDIOCYTOPROTECTORS IN TREATMENT OF ISCHEMIC HEART DISEASE WITH VENTRICULAR ARRHYTHMIAS

open access: yesРоссийский кардиологический журнал, 2016
It is known that ventricular dysrhythmias in patients  with ischemic heart  diasease can be of various origin. Hence selection of antiarrhythmic tactics in such patients should be individual and pathogenetically proved.Aim.
E. A. Ryngach   +4 more
doaj   +1 more source

Integrative Approaches in Cardiovascular Disease: The Role of Nutraceuticals in Heart Failure, Atrial Fibrillation, and Related Conditions

open access: yesPhytotherapy Research, EarlyView.
Schematic representation of the shared pathophysiological mechanisms underlying heart failure (HF) and atrial fibrillation (AF), including inflammation, oxidative stress, endothelial dysfunction, and fibrosis. The figure highlights the clinical and mechanistic convergence of conventional pharmacological therapies and selected nutraceuticals in ...
Laura Beatrice Mattioli   +6 more
wiley   +1 more source

Effect of empiric antiarrhythmic therapy in resuscitated out-of-hospital cardiac arrest victims with coronary artery disease [PDF]

open access: yes, 1990
The effect of empiric antiarrhythmic therapy with quindine and procainamide on long-term mortality was examined in 209 patients with coronary artery disease resuscitated after out-of-hospital cardiac arrest.
Wolfe, Robert A.   +8 more
core   +1 more source

Cardiotoxicity of BRAF/MEK inhibitors

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Rapidly accelerated fibrosarcoma type B/B‐Raf proto‐oncogene, serine/threonine kinase (BRAF) and mitogen‐activated protein kinase (MEK) inhibitors have transformed outcomes in cancer therapy, particularly in melanoma. However, cardiovascular toxicities are increasingly recognized in real‐world clinical practice.
Katharina Seuthe   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy